OGEN Oragenics: Enterprise Value-to-Revenue Multiple

Oragenics, Inc. (OGEN) - corporate logo

The integration of ESG principles and bioethics into the drug development process at Oragenics, Inc. (OGEN) is reflected in the EV/Sales chart dynamics. This trend has led to monetization through royalties and vaccine licenses, while 0.00 captures the current value of the indicator. Business stability is supported by an absence of geopolitical risks, providing the company with a neutral backdrop for global expansion.

OGEN: Oragenics, Inc. Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

OGEN (Oragenics, Inc.): analytical breakdowns and indicator data

- market price and analyst price targets:
- company stock capitalization data:
Fundamental company valuation:OGEN - Oragenics, Inc.
Core merchandise of Oragenics Inc.

This indicator determines the market value of the entire business, including debt, relative to a unit of sales, allowing for an assessment of the premium paid for the generated cash flow. By analyzing the enterprise value-to-annual revenue multiple, an investor can see the resilience of Oragenics, Inc. (OGEN), whose infection-related developments are shielded from geopolitical risks, making the trend of this metric a pure reflection of the market's fundamental expectations.